	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)	CLUSTER	PREPROCESSED_SENTENCE
S48-PMC3702245	PMC3702245	6/2013	S48-PMC3702245	['Vitamin D HAS BEEN SHOWN to upregulate Endogenous Synthesis Of Cathelicidin, a potent Antimicrobial peptide, in response to Microbial Invasion, via activation of toll-like receptors on microphages and Monocytes.6,24given that Antimicrobial peptides provide rapid Defense against invading pathogens, it is PLAUSIBLE that Vitamin D plays a ROLE in host defense against infections in both mother and offspring.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 305), ('SUPERFICIAL_RELATIONSHIP', 338)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0009790', 'embryo development', 39, 'endogenous'), ('GO_0007608', 'sensory perception of smell', 50, 'synthesis of ...'), ('CHEBI_3364', 'Canthiumine', 63, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 63, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 86, 'antimicrobial'), ('NCBITaxon_10088', 'Mus <genus>', 124, 'microbial'), ('GO_0007586', 'digestion', 134, 'invasion'), ('CL_0000576', 'monocyte', 201, 'monocytes'), ('CHEBI_65381', 'albizoside C', 226, 'antimicrobial'), ('GO_0006952', 'defense response', 263, 'defense'), ('CHEBI_27300', 'vitamin D', 320, 'vitamin D')]	0	['vitamin shown upregulate endogenous synthesis , potent antimicrobial peptide, response microbial invasion, via activation toll-like receptors microphages monocytes.6,24given antimicrobial peptides provide rapid defense invading pathogens, plausible  plays role host defense infections mother offspring.']
S186-PMC4302429	PMC4302429	1/2015	S186-PMC4302429	['PRESUMABLY, in addition to Cathelicidin, OTHER Immune Mediators are INVOLVED in the Vitamin D-dependent Immune pathways.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 41), ('SUPERFICIAL_RELATIONSHIP', 68)]	4	[('CHEBI_3364', 'Canthiumine', 27, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 27, 'cathelicidin'), ('UBERON_0002405', 'immune system', 47, 'immune'), ('CHEBI_35222', 'inhibitor', 54, 'mediators'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('UBERON_0002405', 'immune system', 104, 'immune')]	0	['presumably, addition , immune mediators involved -dependent immune pathways.']
S14-PMC4859539	PMC4859539	5/2016	S14-PMC4859539	['additionally, WHILE ONE STUDY examined the levels of maternal and neonatal Vitamin D and Cathelicidin concentrations in healthy children at Delivery, there is a LACK OF research TO DETERMINE CORRELATIONS between Vitamin D status and cathelicidin among healthy children over time [20], as well as WHICH FACTORS such as age of the child, gender, and body composition MAY INDEPENDENTLY IMPACT Cathelicidin concentrations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 161), ('QUESTION_ANSWERED_BY_THIS_WORK', 178), ('SUPERFICIAL_RELATIONSHIP', 191), ('EXPLICIT_QUESTION', 296), ('SUPERFICIAL_RELATIONSHIP', 302), ('INCOMPLETE_EVIDENCE', 365), ('SUPERFICIAL_RELATIONSHIP', 369), ('SUPERFICIAL_RELATIONSHIP', 383)]	10	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 89, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 89, 'cathelicidin'), ('GO_0007567', 'parturition', 140, 'delivery'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 390, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 390, 'cathelicidin')]	0	['additionally, one study examined levels maternal neonatal   concentrations healthy children delivery, lack research determine correlations  status cathelicidin among healthy children time [20], well factors age child, gender, body composition may independently impact  concentrations.']
S97-PMC4859539	PMC4859539	5/2016	S97-PMC4859539	"['[""""in MODELS 1 and 4, there was also a TREND NOTED with the child’s percent fat being positively ASSOCIATED with Cathelicidin (beta = 0.028, p = 0.052 and beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\\n\\ncaption (table-wrap): table 3\\nmultivariable linear regression models assessing factors associated with natural logarithm for Cathelicidin.model 1 \\xa0\\xa0independent variablesbetase1p valuerace/ethnicity\\xa0\\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child\'s current 25(Oh)D-0.0050.010.598 model 2 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child\'s 25(Oh)D at Birth-0.0030.010.748 model 3 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(Oh)D throughout Pregnancy<-0.000100.999 model 4 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(Oh)D 1-month before Delivery0.0030.010.606\\n1se represents standard error\\n\\ndiscussion\\nin THIS STUDY of healthy children whose mothers had participated in a Vitamin D supplementation trial during Pregnancy, DESPITE DIFFERENCES in both maternal and childhood Vitamin D status, there were no significant differences in Cathelicidin concentration between the three racial/ethnic groups studied.""""]']"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 42), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 1391), ('ANOMALY_CURIOUS_FINDING', 1508), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1516)]	7	[('CHEBI_3364', 'Canthiumine', 110, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 110, 'cathelicidin'), ('CHEBI_3461', 'Casuarictin', 337, 'Cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 572, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 572, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 801, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 807, 'D'), ('GO_0007567', 'parturition', 812, 'birth'), ('CHEBI_71657', 'versiconol acetate', 1042, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1048, 'D'), ('GO_0007565', 'female pregnancy', 1061, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 1300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1300, '25(OH)D'), ('GO_0007567', 'parturition', 1323, 'delivery0'), ('CHEBI_27300', 'vitamin D', 1458, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1497, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1559, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 1618, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 1618, 'cathelicidin')]	0	"['[""""in models 1 4, also trend noted child’s percent fat positively associated widin (beta = 0.028, p = 0.052 beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\\n\\ncaption (table-wrap): table 3\\nmultivariable linear regression models assessing factors associated natural logarithm cathelicidin.model 1 \\xa0\\xa0independent variablesbetase1p valuerace/ethnicity\\xa0\\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child*s current 25(oh)d-0.0050.010.598 model 2 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child*s 25(oh)d birth-0.0030.010.748 model 3 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(oh)d throughout pregnancy<-0.000100.999 model 4 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(oh)d 1-month delivery0.0030.010.606\\n1se represents standard error\\n\\ndiscussion\\nin sealthy children whose mothers participated vitamin supplementation trial p despite differences maternal childhoostatus, significant differences cathelicidin concentration three racial/ethnic groups studied.""""]']"
S99-PMC4859539	PMC4859539	5/2016	S99-PMC4859539	['REGARDLESS OF Vitamin D status, there was no statistically significant difference in Cathelicidin concentrations between subjects, CONSISTENT with the FINDINGS of other RECENT STUDIES [6,7,12,14,17,20].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 169)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 85, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 85, 'cathelicidin')]	0	['regardless  status, statistically significant difference  concentrations subjects, consistent findings recent studies [6,7,12,14,17,20].']
S104-PMC4859539	PMC4859539	5/2016	S104-PMC4859539	['additionally, the LACK OF CORRELATION MAY SUGGEST that circulating Cathelicidin concentration is NOT REFLECTIVE of WHAT is happening at the cellular level, and in this regard, cathelicidin mrna Expression by Immune Cells or target Tissue MAY BE a BETTER indicator of Vitamin D’s long-term EFFECT on the Cathelicidin system.']	[('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 42), ('FULL_UNKNOWN', 97), ('EXPLICIT_QUESTION', 115), ('INCOMPLETE_EVIDENCE', 238), ('FUTURE_PREDICTION', 247), ('SUPERFICIAL_RELATIONSHIP', 289)]	9	[('CHEBI_3364', 'Canthiumine', 67, 'cathelicidin'), ('GO_0010467', 'gene expression', 194, 'expression'), ('CL_0000738', 'leukocyte', 208, 'immune cells'), ('UBERON_0002405', 'immune system', 208, 'immune'), ('UBERON_0000479', 'tissue', 231, 'tissue'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 303, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 303, 'cathelicidin')]	0	['additionally, lack correlation may suggest circulating  concentration reflective happening cellular level, regard, cathelicidin mrna expression immune cells target tissue may better indicator ’s long-term effect  system.']
S106-PMC4934634	PMC4934634	11/2015	S106-PMC4934634	['cathelicidins, Antimicrobial peptides that can defend against pathogens, are up regulated by Vitamin D. vdr can bind to response elements Of the Human Cathelicidin peptide Gene (Cathelicidin Antimicrobial peptide; camp) increasing the Killing ability of Innate Immune Cells, Macrophages, THUS strengthening the innate Immune System’s response [41].']	[('PROBABLE_UNDERSTANDING', 288)]	1	[('CHEBI_65381', 'albizoside C', 15, 'antimicrobial'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('SO_0001467', 'RST', 138, 'of'), ('NCBITaxon_9606', 'Homo sapiens', 145, 'human'), ('PR_000006009', 'alpha-catulin', 151, 'cathelicidin'), ('SO_0000704', 'gene', 172, 'gene'), ('CHEBI_3364', 'Canthiumine', 178, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 178, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 191, 'antimicrobial'), ('GO_0007601', 'visual perception', 235, 'killing'), ('CL_0002088', 'interstitial cell of Cajal', 254, 'innate immune cells'), ('GO_0044409', 'entry into host', 254, 'innate immune cells'), ('UBERON_0002405', 'immune system', 261, 'immune'), ('CL_0000235', 'macrophage', 275, 'macrophages'), ('UBERON_0002405', 'immune system', 318, 'immune system')]	0	['cathelicidins, antimicrobial peptides defend pathogens, regulated . vdr bind response elements human cathelicidin peptide gene ( antimicrobial peptide; camp) increasing killing ability innate immune cells, macrophages, thus strengthening innate immune system’s response [41].']
S22-PMC5679631	PMC5679631	11/2017	S22-PMC5679631	['in addition, a study of sepsis patients DEMONSTRATED a positive ASSOCIATION between Vitamin D status and Plasma Cathelicidin concentrations [10].']	[('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 64)]	2	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 105, 'plasma'), ('CHEBI_3364', 'Canthiumine', 112, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 112, 'cathelicidin')]	0	['addition, study sepsis patients demonstrated positive association  status plasma  concentrations [10].']
S20-PMC3501517	PMC3501517	11/2012	S20-PMC3501517	['Macrophage Release Of Cathelicidin, an Antimicrobial peptide required for efficient Macrophage Killing of mtb , in response to toll-like receptor activation requires co-activation of the Vitamin D receptor[19],[20].']	N/A	N/A	[('CL_0000235', 'macrophage', 0, 'Macrophage'), ('GO_0046661', 'male sex differentiation', 0, 'Macrophage'), ('GO_1990864', 'response to growth hormone-releasing hormone', 11, 'release of cathelicidin'), ('CHEBI_3364', 'Canthiumine', 22, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 22, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 39, 'antimicrobial'), ('CL_0000235', 'macrophage', 84, 'macrophage'), ('GO_0007601', 'visual perception', 95, 'killing'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]	0	['macrophage release , antimicrobial peptide required efficient macrophage killing mtb , response toll-like receptor activation requires co-activation  receptor[19],[20].']
S376-PMC4448820	PMC4448820	5/2015	S376-PMC4448820	['Histone Acetylation Controls Cathelicidin Gene Expression by Vitamin D in Keratinocytes (219).']	N/A	N/A	[('CHEBI_15358', 'histone', 0, 'Histone'), ('GO_0034729', 'histone H3-K79 methylation', 0, 'Histone acetylation'), ('PR_000027594', 'histone H3', 0, 'Histone'), ('GO_0065007', 'biological regulation', 20, 'controls'), ('CHEBI_3364', 'Canthiumine', 29, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 29, 'cathelicidin'), ('GO_0010467', 'gene expression', 42, 'gene expression'), ('SO_0000704', 'gene', 42, 'gene'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CL_0000312', 'keratinocyte', 74, 'keratinocytes')]	0	['histone acetylation controls  gene expression  keratinocytes (219).']
S52-PMC4859539	PMC4859539	5/2016	S52-PMC4859539	['results\n\ncohort\nwhile 194 children had participated in the follow-up study (55% of the original cohort participating in the Vitamin D Pregnancy study), 133 (38%) had a Blood sample obtained at the time of the study visit and thus, were able to have Cathelicidin measured.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_3364', 'Canthiumine', 249, 'cathelicidin')]	0	['results\n\ncohort\nwhile 194 children participated follow-up study (55% original cohort participating  pregnancy study), 133 (38%) blood sample obtained time study visit thus, able  measured.']
S57-PMC4859539	PMC4859539	5/2016	S57-PMC4859539	"['[""""of infections in the last year [median (range)]1.0 (0.0–5.0)child’s daily Vitamin D intake at time of visit (iu/day)1205.3 ± 109.8 (17.1–512.5)child\'s 25(Oh)D at time of visit (ng/ml)127.2 ± 9.4 (8.3–61.5)child\'s Vitamin D status at time of visit\\xa0\\xa0\\xa0\\xa0\\xa0sufficient (≥20 ng/ml) [n (%)]106 (79.7)\\xa0\\xa0\\xa0\\xa0deficient (<20 ng/ml) [n (%)]27 (20.3)total circulating 25(Oh)D (ng/ml) at Birth122.8 ± 9.8 (3.6–47.8)maternal 25(Oh)D (ng/ml) within 1 month prior to Delivery139.2 ± 15.0 (10.0–78.6)maternal 25(Oh)D area under curve, Pregnancy visits 3–71153.1 ± 44.6 (50.1–251.4)\\n1mean±std (range)\\n\\nstudy outcomes\\nthe median Cathelicidin concentration for the entire cohort was 28.1 ng/ml, ranging from 5.6 to 3368.6 ng/ml.""""]']"	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 154, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 157, 'D'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 351, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 351, '25 ... OH ... D'), ('GO_0042750', 'hibernation', 370, 'birth122'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0030324', 'lung development', 446, 'delivery139'), ('CHEBI_71657', 'versiconol acetate', 487, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 487, '25(OH)D'), ('GO_0007565', 'female pregnancy', 513, 'pregnancy'), ('CHEBI_3364', 'Canthiumine', 605, 'cathelicidin')]	0	"['[""""of infections last year [median (range)]1.0 (0.0–5.0)child’s dain intake time visit (iu/day)1205.3 ± 109.8 (17.1–512.5)child*s 25(oh)d time visit (ng/ml)127.2 ± 9.4 (8.3–61.5)childn status time visit\\xa0\\xa0\\xa0\\xa0\\xa0sufficient (≥20 ng/ml) [n (%)]106 (79.7)\\xa0\\xa0\\xa0\\xa0deficient (<20 ng/ml) [n (%)]27 (20.3)total circulating 25(oh)d (ng/ml) birth122.8 ± 9.8 (3.6–47.8)maternal 25(oh)d (ng/ml) within 1 month prior delivery139.2 ± 15.0 (10.0–78.6)maternal 25(oh)d area curve, pregnancy visits 3–71153.1 ± 44.6 (50.1–251.4)\\n1mean±std (ran outcomes\\nthe median cathelicidin concentration entire cohort 28.1 ng/ml, ranging 5.6 3368.6 ng/ml.""""]']"
S81-PMC4859539	PMC4859539	5/2016	S81-PMC4859539	['in Vitamin D deficient children, there were no statistically significant differences between Cathelicidin concentration among the races/ethnicities or by gender.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 93, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 93, 'cathelicidin')]	0	[' deficient children, statistically significant differences  concentration among races/ethnicities gender.']
S67-PMC3347028	PMC3347028	3/2012	S67-PMC3347028	['serum samples taken from african american subjects with low 25(oh)d were inefficient in supporting cathelicidin mrna induction; however, with the addition of 25(oh)d to those samples with low 25(oh)d levels this pattern was reversed.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('SUPERFICIAL_RELATIONSHIP', 212)]	2	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('CHEBI_3364', 'Canthiumine', 99, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 99, 'cathelicidin'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 161, 'OH)D'), ('CHEBI_71657', 'versiconol acetate', 192, '25(OH)D')]	0	['serum samples taken african american subjects low 25(oh)d inefficient supporting  mrna induction; however, addition 25(oh)d samples low 25(oh)d levels pattern reversed.']
S68-PMC3347028	PMC3347028	3/2012	S68-PMC3347028	['thus, in this series of experiments, the addition of 25(oh)d3restored the ability of sera from individuals with low 25(oh)d concentrations to support tlr2/1l-mediated induction of cathelicidin mrna.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_51981', 'DY-732', 53, '25(OH)D3restored'), ('UBERON_0001977', 'blood serum', 85, 'sera'), ('NCBITaxon_1', 'root', 95, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('PR_000001155', 'Toll-like receptor 4', 150, 'TLR2'), ('CHEBI_3364', 'Canthiumine', 180, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 180, 'cathelicidin')]	0	['thus, series experiments, addition 25(oh)d3restored ability sera individuals low 25(oh)d concentrations support tlr2/1l-mediated induction  mrna.']
S111-PMC3347028	PMC3347028	3/2012	S111-PMC3347028	['thus, there are different deficiency set points: the risk of rickets increases significantly when total circulating 25(oh)d falls below 10 ng/ml (25 nmol/l) whereas cathelicidin mrna expression as a marker of immune function continues to be suppressed until 25(oh)d circulating levels reach at least 20 ng/ml (50 nmol/l) [69].']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 157), ('PROBABLE_UNDERSTANDING', 194), ('IMPORTANT_CONSIDERATION', 291)]	5	[('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 116, '25(OH)D'), ('CHEBI_3364', 'Canthiumine', 165, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 165, 'cathelicidin'), ('GO_0010467', 'gene expression', 183, 'expression'), ('UBERON_0002405', 'immune system', 209, 'immune'), ('CHEBI_71657', 'versiconol acetate', 258, '25(OH)D')]	0	['thus, different deficiency set points: risk rickets increases significantly total circulating 25(oh)d falls 10 ng/ml (25 nmol/l) whereas  mrna expression marker immune function continues suppressed 25(oh)d circulating levels reach least 20 ng/ml (50 nmol/l) [69].']
S31-PMC3356951	PMC3356951	4/2012	S31-PMC3356951	['[614] 1,25(oh)2d has a wide range of biological actions, such as inhibition of cellular proliferation and inducing terminal differentiation, inhibiting angiogenesis, stimulating insulin production, inhibiting renin production, and stimulating macrophage cathelicidin production.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 23)]	1	[('CHEBI_37958', 'dye', 6, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 8, '25(OH)2D'), ('GO_0008283', 'cell proliferation', 79, 'cellular proliferation'), ('GO_0001525', 'angiogenesis', 152, 'angiogenesis'), ('PR_000045358', 'insulin family protein', 178, 'insulin'), ('PR_000014368', 'RuvB-like 1', 209, 'renin'), ('CL_0000235', 'macrophage', 243, 'macrophage'), ('CHEBI_3364', 'Canthiumine', 254, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 254, 'cathelicidin')]	0	['[614] 1,25(oh)2d wide range biological actions, inhibition cellular proliferation inducing terminal differentiation, inhibiting angiogenesis, stimulating insulin production, inhibiting renin production, stimulating macrophage  production.']
S88-PMC4251419	PMC4251419	12/2014	S88-PMC4251419	['this stimulates autophagy (the degradation of internal cell structures) and the synthesis of antimicrobials, such as cathelicidin, for bacterial killing [54].']	N/A	N/A	[('GO_0006914', 'autophagy', 16, 'autophagy'), ('GO_0009990', 'contact guidance', 31, 'degradation of ... cell structures'), ('GO_0009057', 'macromolecule catabolic process', 80, 'synthesis'), ('CHEBI_22583', 'antifeedant', 93, 'antimicrobials'), ('GO_0043277', 'apoptotic cell clearance', 93, 'antimicrobials'), ('CHEBI_3364', 'Canthiumine', 117, 'cathelicidin'), ('GO_0007601', 'visual perception', 145, 'killing')]	0	['stimulates autophagy (the degradation internal cell structures) synthesis antimicrobials, , bacterial killing [54].']
S37-PMC4303849	PMC4303849	1/2015	S37-PMC4303849	[', cathelicidin hctd, ll-37 [23,24]) and detoxification ( i.e.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 2, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 2, 'cathelicidin'), ('PR_000009809', 'leukocyte immunoglobulin-like receptor subfamily B member 2', 21, 'LL-37'), ('GO_0098754', 'detoxification', 40, 'detoxification')]	0	[',  hctd, ll-37 [23,24]) detoxification ( i.e.']
S4-PMC4859539	PMC4859539	5/2016	S4-PMC4859539	['statistical analyses compared cathelicidin concentrations with concentrations of 25(oh)d at various time points (maternal levels throughout pregnancy, at birth, and child’s current level); and with race/ethnicity, age, gender, bmi, percent fat, and frequency of infections using student’s t-test, χ2, wilcoxon ranked-sum analysis, and multivariate regression.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 30, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('GO_0007565', 'female pregnancy', 140, 'pregnancy'), ('GO_0007567', 'parturition', 154, 'birth')]	0	['statistical analyses compared  concentrations concentrations 25(oh)d various time points (maternal levels throughout pregnancy, birth, child’s current level); race/ethnicity, age, gender, bmi, percent fat, frequency infections using student’s t-test, χ2, wilcoxon ranked-sum analysis, multivariate regression.']
S5-PMC4859539	PMC4859539	5/2016	S5-PMC4859539	['the cohort’s median cathelicidin concentration was 28.1 ng/ml (range: 5.6–3368.6) and did not correlate with 25(oh)d, but was positively correlated with advancing age (ρ = 0.236 & p = 0.005, respectively).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('SUPERFICIAL_RELATIONSHIP', 137)]	2	[('CHEBI_3364', 'Canthiumine', 20, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 109, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 109, '25(OH)D')]	0	['cohort’s median  concentration 28.1 ng/ml (range: 5.6–3368.6) correlate 25(oh)d, positively correlated advancing age (ρ = 0.236 & p = 0.005, respectively).']
S6-PMC4859539	PMC4859539	5/2016	S6-PMC4859539	['forty patients evaluated at two visits showed an increase of 24.0 ng/ml in cathelicidin from the first visit to the next (p<0.0001).']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 75, 'cathelicidin')]	0	['forty patients evaluated two visits showed increase 24.0 ng/ml  first visit next (p<0.0001).']
S7-PMC4859539	PMC4859539	5/2016	S7-PMC4859539	['increased age and male gender were correlated with increased cathelicidin when controlling for race/ethnicity, percent fat, and child’s current 25(oh)d concentration (p = 0.028 & p = 0.047, respectively).']	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('CHEBI_3364', 'Canthiumine', 61, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 144, '25(OH)D')]	0	['increased age male gender correlated increased  controlling race/ethnicity, percent fat, child’s current 25(oh)d concentration (p = 0.028 & p = 0.047, respectively).']
S8-PMC4859539	PMC4859539	5/2016	S8-PMC4859539	['this study demonstrated that as children age, the concentration of cathelicidin increases.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11)]	2	[('CHEBI_3364', 'Canthiumine', 67, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 67, 'cathelicidin')]	0	['study demonstrated children age, concentration  increases.']
S9-PMC4859539	PMC4859539	5/2016	S9-PMC4859539	['furthermore, male gender was significantly associated with increased cathelicidin concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 43)]	1	[('CHEBI_3364', 'Canthiumine', 69, 'cathelicidin')]	0	['furthermore, male gender significantly associated increased  concentrations.']
S18-PMC4859539	PMC4859539	5/2016	S18-PMC4859539	['it was hypothesized that (1) total current circulating 25(oh)d would be positively correlated with cathelicidin in children; (2) children with higher plasma cathelicidin concentrations would have had fewer infections than children with lower cathelicidin concentrations; and (3) cathelicidin concentration would increase with advancing age.']	[('INCOMPLETE_EVIDENCE', 7), ('FUTURE_PREDICTION', 63), ('SUPERFICIAL_RELATIONSHIP', 83), ('FUTURE_PREDICTION', 185), ('FUTURE_PREDICTION', 306)]	5	[('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 150, 'plasma'), ('CHEBI_3364', 'Canthiumine', 157, 'cathelicidin'), ('CHEBI_3364', 'Canthiumine', 242, 'cathelicidin'), ('CHEBI_3364', 'Canthiumine', 279, 'cathelicidin')]	0	['hypothesized (1) total current circulating 25(oh)d would positively correlated cathelicidin children; (2) children higher plasma  concentrations would fewer infections children lower  concentrations; (3)  concentration would increase advancing age.']
S39-PMC4859539	PMC4859539	5/2016	S39-PMC4859539	['samples with concentrations above the standard curve upper limit were diluted further due to their higher cathelicidin concentration.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 106, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 106, 'cathelicidin')]	0	['samples concentrations standard curve upper limit diluted due higher  concentration.']
S41-PMC4859539	PMC4859539	5/2016	S41-PMC4859539	['the detection limit of the human cathelicidin elisa was 0.14 ng/ml.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 27, 'human'), ('CHEBI_3364', 'Canthiumine', 33, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 33, 'cathelicidin')]	0	['detection limit human  elisa 0.14 ng/ml.']
S42-PMC4859539	PMC4859539	5/2016	S42-PMC4859539	['statistical analysis\nanalysis was completed using the cathelicidin concentration values obtained from each child’s yearly follow-up visit.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 54, 'cathelicidin')]	0	['statistical analysis\nanalysis completed using  concentration values obtained child’s yearly follow-up visit.']
S43-PMC4859539	PMC4859539	5/2016	S43-PMC4859539	['spearman correlations (ρ) were used to assess the association between each child’s cathelicidin concentration and the 25(oh)d concentrations obtained at various time points: (1) at the corresponding follow-up visit; (2) at delivery; (3) maternal concentration of 25(oh)d throughout pregnancy (using the area under the curve from visit 3 to visit 7); and (4) maternal concentration of 25(oh)d within one month of delivery.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 83, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 118, '25(OH)D'), ('GO_0007567', 'parturition', 223, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 263, '25(OH)D'), ('GO_0007565', 'female pregnancy', 282, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 384, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 384, '25(OH ... D'), ('GO_0007567', 'parturition', 412, 'delivery')]	0	['spearman correlations (ρ) used assess association child’s  concentration 25(oh)d concentrations obtained various time points: (1) corresponding follow-up visit; (2) delivery; (3) maternal concentration 25(oh)d throughout pregnancy (using area curve visit 3 visit 7); (4) maternal concentration 25(oh)d within one month delivery.']
S44-PMC4859539	PMC4859539	5/2016	S44-PMC4859539	['each child’s cathelicidin concentration also was compared to the frequency of infections each child had diagnosed within the last year, and to the age of the child.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 13, 'cathelicidin')]	0	['child’s  concentration also compared frequency infections child diagnosed within last year, age child.']
S45-PMC4859539	PMC4859539	5/2016	S45-PMC4859539	['a post-hoc analysis was conducted to determine if bmi and percent fat had an effect on cathelicidin concentration.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 47), ('SUPERFICIAL_RELATIONSHIP', 77)]	3	[('CHEBI_3364', 'Canthiumine', 87, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 87, 'cathelicidin')]	0	['post-hoc analysis conducted determine bmi percent fat effect  concentration.']
S46-PMC4859539	PMC4859539	5/2016	S46-PMC4859539	['in the 40 children in whom repeat yearly cathelicidin concentrations were available, a wilcoxon signed rank test of paired samples was performed.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 41, 'cathelicidin')]	0	['40 children repeat yearly  concentrations available, wilcoxon signed rank test paired samples performed.']
S53-PMC4859539	PMC4859539	5/2016	S53-PMC4859539	['table 1 shows the demographics and clinical characteristics of the 133 children participants in this study with measurement of circulating cathelicidin.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 139, 'cathelicidin')]	0	['table 1 shows demographics clinical characteristics 133 children participants study measurement circulating .']
S58-PMC4859539	PMC4859539	5/2016	S58-PMC4859539	['three subjects had cathelicidin concentrations that were more than two times greater than the next lowest concentration.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 19, 'cathelicidin')]	0	['three subjects  concentrations two times greater next lowest concentration.']
S59-PMC4859539	PMC4859539	5/2016	S59-PMC4859539	['these subjects had cathelicidin values of 737.5, 2000.4, and 3368.6 ng/ml, while the next highest value was 195.6 ng/ml.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 19, 'cathelicidin')]	0	['subjects  values 737.5, 2000.4, 3368.6 ng/ml, next highest value 195.6 ng/ml.']
S60-PMC4859539	PMC4859539	5/2016	S60-PMC4859539	['the subjects with the three highest cathelicidin concentration values had characteristics including 25(oh)d, bmi, percent fat, race/ethnicity, and age, which were comparable to the corresponding variable represented in the entire cohort.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 36, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 100, '25(OH)D')]	0	['subjects three highest  concentration values characteristics including 25(oh)d, bmi, percent fat, race/ethnicity, age, comparable corresponding variable represented entire cohort.']
S71-PMC4859539	PMC4859539	5/2016	S71-PMC4859539	['cathelicidin (ng/ml)characteristicmedian (iqr)1p-valuerace/ethnicity0.999\xa0\xa0\xa0\xa0black26.8 (23.3, 41.6)\xa0\xa0\xa0\xa0\xa0white27.7 (18.0, 51.9)\xa0\xa0\xa0\xa0\xa0hispanic30.2 (20.2, 39.0)\xa0vitamin d status at follow-up visit0.78\xa0\xa0\xa0\xa0deficient (<20 ng/ml)27.4 (19.8, 35.9)\xa0\xa0\xa0\xa0\xa0sufficient (≥20 ng/ml)29.6 (20.2, 43.2)\xa0\n1iqr represents 25th and 75th percentile\nno significant overall correlation existed between the children’s cathelicidin concentration and the children’s 25(oh)d concentration at the time of follow-up visit, nor did one exist when the cohort was stratified by race/ethnicity.']	N/A	N/A	[('CHEBI_3461', 'Casuarictin', 0, 'Cathelicidin'), ('PR_000004907', 'complement component C7', 0, 'Cathelicidin'), ('CHEBI_28384', 'vitamin K', 157, 'Vitamin D'), ('CHEBI_3364', 'Canthiumine', 391, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 437, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 437, '25(OH ... D')]	0	['cathelicidin (ng/ml)characteristicmedian (iqr)1p-valuerace/ethnicity0.999\xa0\xa0\xa0\xa0black26.8 (23.3, 41.6)\xa0\xa0\xa0\xa0\xa0white27.7 (18.0, 51.9)\xa0\xa0\xa0\xa0\xa0hispanic30.2 (20.2, 39.0)\xa0vitamin status follow-up visit0.78\xa0\xa0\xa0\xa0deficient (<20 ng/ml)27.4 (19.8, 35.9)\xa0\xa0\xa0\xa0\xa0sufficient (≥20 ng/ml)29.6 (20.2, 43.2)\xa0\n1iqr represents 25th 75th percentile\nno significant overall correlation existed children’s  concentration children’s 25(oh)d concentration time follow-up visit, one exist cohort stratified race/ethnicity.']
S73-PMC4859539	PMC4859539	5/2016	S73-PMC4859539	['neither bmi, nor percent fat were found to correlate with cathelicidin concentration.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 58, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 58, 'cathelicidin')]	0	['neither bmi, percent fat found correlate  concentration.']
S74-PMC4859539	PMC4859539	5/2016	S74-PMC4859539	['within the entire cohort, age of the child and cathelicidin concentration demonstrated a positive correlation (ρ = 0.236, p = 0.005).']	[('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 98)]	2	[('CHEBI_3364', 'Canthiumine', 47, 'cathelicidin')]	0	['within entire cohort, age child  concentration demonstrated positive correlation (ρ = 0.236, p = 0.005).']
S75-PMC4859539	PMC4859539	5/2016	S75-PMC4859539	['as the age of the child increased, the concentration of cathelicidin also increased ( fig 1 ).']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 56, 'cathelicidin')]	0	['age child increased, concentration  also increased ( fig 1 ).']
S78-PMC4859539	PMC4859539	5/2016	S78-PMC4859539	['there was a significant positive correlation between age and cathelicidin concentration (ρ = 0.236, p = 0.005); ρ value represents spearman correlation.']	[('SUPERFICIAL_RELATIONSHIP', 33)]	1	[('CHEBI_3364', 'Canthiumine', 61, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 61, 'cathelicidin')]	0	['significant positive correlation age  concentration (ρ = 0.236, p = 0.005); ρ value represents spearman correlation.']
S79-PMC4859539	PMC4859539	5/2016	S79-PMC4859539	['the upper and lower edges of the box represent the 75thpercentile and the 25thpercentile of cathelicidin concentration, respectively, measured by elisa and reported in ng/ml.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 92, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 92, 'cathelicidin')]	0	['upper lower edges box represent 75thpercentile 25thpercentile  concentration, respectively, measured elisa reported ng/ml.']
S83-PMC4859539	PMC4859539	5/2016	S83-PMC4859539	['when comparing cathelicidin concentrations of children who were deficient with those who were sufficient, (25(oh)d concentrations ≥20 ng/ml), there were no statistically significant differences.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 15, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 15, 'cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D')]	0	['comparing  concentrations children deficient sufficient, (25(oh)d concentrations ≥20 ng/ml), statistically significant differences.']
S84-PMC4859539	PMC4859539	5/2016	S84-PMC4859539	['in the group of children with a total circulating 25(oh)d concentration ≥20 ng /ml, cathelicidin concentration was significantly positively associated with age (ρ = 0.373, p = 0.0002).']	[('SUPERFICIAL_RELATIONSHIP', 140)]	1	[('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 50, '25(OH)D'), ('CHEBI_3364', 'Canthiumine', 84, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 84, 'cathelicidin')]	0	['group children total circulating 25(oh)d concentration ≥20 ng /ml,  concentration significantly positively associated age (ρ = 0.373, p = 0.0002).']
S85-PMC4859539	PMC4859539	5/2016	S85-PMC4859539	['within this same group, cathelicidin concentration was negatively associated with the number of documented infections a child experienced in the last year (ρ = -0.205, p = 0.047).']	[('SUPERFICIAL_RELATIONSHIP', 66)]	1	[('CHEBI_3364', 'Canthiumine', 24, 'cathelicidin')]	0	['within group,  concentration negatively associated number documented infections child experienced last year (ρ = -0.205, p = 0.047).']
S89-PMC4859539	PMC4859539	5/2016	S89-PMC4859539	['in a subset of 40 children with two consecutive visits roughly twelve months apart, the median increase in cathelicidin concentration from the first visit to the second visit was 24.0 ng/ml (ranging from -1.9 ng/ml to +223.4ng/ml, p≤0.0001); ρ value represents spearman correlation.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 107, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 107, 'cathelicidin')]	0	['subset 40 children two consecutive visits roughly twelve months apart, median increase  concentration first visit second visit 24.0 ng/ml (ranging -1.9 ng/ml +223.4ng/ml, p≤0.0001); ρ value represents spearman correlation.']
S90-PMC4859539	PMC4859539	5/2016	S90-PMC4859539	['the upper and lower edges of the box represent the 75thpercentile and the 25thpercentile of cathelicidin concentration, respectively, reported in ng/ml.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 92, 'cathelicidin')]	0	['upper lower edges box represent 75thpercentile 25thpercentile  concentration, respectively, reported ng/ml.']
S91-PMC4859539	PMC4859539	5/2016	S91-PMC4859539	['table 3 summarizes the results of the 4 multivariable linear regression models assessing factors associated with the natural logarithm of the cathelicidin concentration.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 142, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 142, 'cathelicidin')]	0	['table 3 summarizes results 4 multivariable linear regression models assessing factors associated natural logarithm  concentration.']
S93-PMC4859539	PMC4859539	5/2016	S93-PMC4859539	['in each of the models, however, the child’s age at their first follow-up visit was significantly and independently positively correlated with cathelicidin.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 23), ('SUPERFICIAL_RELATIONSHIP', 101), ('SUPERFICIAL_RELATIONSHIP', 126)]	3	[('CHEBI_3364', 'Canthiumine', 142, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 142, 'cathelicidin')]	0	['models, however, child’s age first follow-up visit significantly independently positively correlated .']
S96-PMC4859539	PMC4859539	5/2016	S96-PMC4859539	['in models 1 and 4), higher cathelicidin concentrations were significantly associated with male gender (beta = 0.318, p = 0.047), indicating that after adjusting for the other variables in the model, males’ cathelicidin levels were 1.4 times higher than females’.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('SUPERFICIAL_RELATIONSHIP', 74), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 192)]	4	[('CHEBI_3364', 'Canthiumine', 27, 'cathelicidin'), ('CHEBI_3364', 'Canthiumine', 206, 'cathelicidin')]	0	['models 1 4), higher  concentrations significantly associated male gender (beta = 0.318, p = 0.047), indicating adjusting variables model, males’  levels 1.4 times higher females’.']
S100-PMC4859539	PMC4859539	5/2016	S100-PMC4859539	['varying observations, however, have been made when determining whether a correlation between 25(oh)d and cathelicidin concentrations exists.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('INCOMPLETE_EVIDENCE', 31), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63)]	4	[('CHEBI_71657', 'versiconol acetate', 93, '25(OH)D'), ('CHEBI_3364', 'Canthiumine', 105, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 105, 'cathelicidin')]	0	['varying observations, however, made determining whether correlation 25(oh)d  concentrations exists.']
S106-PMC4859539	PMC4859539	5/2016	S106-PMC4859539	['in this study, bmi and percent fat were analyzed with cathelicidin concentrations.']	N/A	N/A	[('CHEBI_3364', 'Canthiumine', 54, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 54, 'cathelicidin')]	0	['study, bmi percent fat analyzed  concentrations.']
S108-PMC4859539	PMC4859539	5/2016	S108-PMC4859539	['this result is consistent with the findings of jeng et al., who also showed no correlation with bmi and cathelicidin in adults with sepsis [9].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 69)]	3	[('CHEBI_3364', 'Canthiumine', 104, 'cathelicidin'), ('UBERON_0007023', 'adult organism', 120, 'adults')]	0	['result consistent findings jeng et al., also showed correlation bmi  adults sepsis [9].']
S109-PMC4859539	PMC4859539	5/2016	S109-PMC4859539	['although not significant, a negative trend was seen between the number of infections a child experienced and cathelicidin concentration.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 37)]	2	[('CHEBI_3364', 'Canthiumine', 109, 'cathelicidin')]	0	['although significant, negative trend seen number infections child experienced  concentration.']
S113-PMC4859539	PMC4859539	5/2016	S113-PMC4859539	['as individuals aged, the concentration of cathelicidin increased.']	N/A	N/A	[('NCBITaxon_1', 'root', 3, 'individuals'), ('CHEBI_3364', 'Canthiumine', 42, 'cathelicidin')]	0	['individuals aged, concentration  increased.']
S118-PMC4859539	PMC4859539	5/2016	S118-PMC4859539	['notably, in the aforementioned study examining localized cathelicidin concentrations in saliva, the female gender was found to positively correlate with cathelicidin [30].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 138)]	3	[('CHEBI_3364', 'Canthiumine', 57, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 57, 'cathelicidin'), ('UBERON_0004339', 'vault of skull', 88, 'saliva')]	0	['notably, aforementioned study examining localized  concentrations saliva, female gender found positively correlate cathelicidin [30].']
S125-PMC4859539	PMC4859539	5/2016	S125-PMC4859539	['in conclusion, this study is the first to examine cathelicidin concentrations in healthy children over time.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 33)]	3	[('CHEBI_3364', 'Canthiumine', 50, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 50, 'cathelicidin')]	0	['conclusion, study first examine  concentrations healthy children time.']
S126-PMC4859539	PMC4859539	5/2016	S126-PMC4859539	['it assists in identifying the normal ranges of circulating cathelicidin concentrations found in healthy children.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 14)]	2	[('CHEBI_3364', 'Canthiumine', 59, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 59, 'cathelicidin')]	0	['assists identifying normal ranges circulating  concentrations found healthy children.']
